The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurological Biomarkers Market Research Report 2025
Synopsis
The global market for Neurological Biomarkers was valued at US$ 8687 million in the year 2024 and is projected to reach a revised size of US$ 19000 million by 2031, growing at a CAGR of 12.0% during the forecast period.
A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.
Global Neurological Biomarkers key players include Thermo Fisher Scientific, Merck, Quest Diagnostics, Abbott, etc. Global top four manufacturers hold a share about 25%.
North America is the largest market, with a share over 55%, followed by Europe, and Asia-Pacific, both have a share over 35 percent.
In terms of product, Proteomics is the largest segment, with a share about 30%. And in terms of application, the largest application is Proteomics, followed by Drug Discovery, Personalized Medicine, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neurological Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurological Biomarkers.
The Neurological Biomarkers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurological Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurological Biomarkers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Thermo Fisher Scientific
Merck
Quest Diagnostics
Abbott
Roche
Illumina
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Cisbio Bioassays
Athena Diagnostics
BGI
Wuxi APP
Aepodia
Proteome Sciences
Genewiz
Segment by Type
Proteomics
Genomics
Imaging
Bioinformatics
Others
Segment by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neurological Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neurological Biomarkers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for Neurological Biomarkers was valued at US$ 8687 million in the year 2024 and is projected to reach a revised size of US$ 19000 million by 2031, growing at a CAGR of 12.0% during the forecast period.
A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.
Global Neurological Biomarkers key players include Thermo Fisher Scientific, Merck, Quest Diagnostics, Abbott, etc. Global top four manufacturers hold a share about 25%.
North America is the largest market, with a share over 55%, followed by Europe, and Asia-Pacific, both have a share over 35 percent.
In terms of product, Proteomics is the largest segment, with a share about 30%. And in terms of application, the largest application is Proteomics, followed by Drug Discovery, Personalized Medicine, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neurological Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurological Biomarkers.
The Neurological Biomarkers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurological Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurological Biomarkers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Thermo Fisher Scientific
Merck
Quest Diagnostics
Abbott
Roche
Illumina
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Cisbio Bioassays
Athena Diagnostics
BGI
Wuxi APP
Aepodia
Proteome Sciences
Genewiz
Segment by Type
Proteomics
Genomics
Imaging
Bioinformatics
Others
Segment by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neurological Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neurological Biomarkers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Neurological Biomarkers Market Overview
1.1 Product Definition
1.2 Neurological Biomarkers by Type
1.2.1 Global Neurological Biomarkers Market Value Comparison by Type (2024 VS 2031)
1.2.2 Proteomics
1.2.3 Genomics
1.2.4 Imaging
1.2.5 Bioinformatics
1.2.6 Others
1.3 Neurological Biomarkers by Application
1.3.1 Global Neurological Biomarkers Market Value by Application (2024 VS 2031)
1.3.2 Diagnostics
1.3.3 Drug Discovery
1.3.4 Personalized Medicine
1.3.5 Others
1.4 Global Neurological Biomarkers Market Size Estimates and Forecasts
1.4.1 Global Neurological Biomarkers Revenue 2020-2031
1.4.2 Global Neurological Biomarkers Sales 2020-2031
1.4.3 Global Neurological Biomarkers Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Neurological Biomarkers Market Competition by Manufacturers
2.1 Global Neurological Biomarkers Sales Market Share by Manufacturers (2020-2025)
2.2 Global Neurological Biomarkers Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Neurological Biomarkers Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Neurological Biomarkers, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neurological Biomarkers, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurological Biomarkers, Product Type & Application
2.7 Global Key Manufacturers of Neurological Biomarkers, Date of Enter into This Industry
2.8 Global Neurological Biomarkers Market Competitive Situation and Trends
2.8.1 Global Neurological Biomarkers Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Neurological Biomarkers Players Market Share by Revenue
2.8.3 Global Neurological Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neurological Biomarkers Market Scenario by Region
3.1 Global Neurological Biomarkers Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Neurological Biomarkers Sales by Region: 2020-2031
3.2.1 Global Neurological Biomarkers Sales by Region: 2020-2025
3.2.2 Global Neurological Biomarkers Sales by Region: 2026-2031
3.3 Global Neurological Biomarkers Revenue by Region: 2020-2031
3.3.1 Global Neurological Biomarkers Revenue by Region: 2020-2025
3.3.2 Global Neurological Biomarkers Revenue by Region: 2026-2031
3.4 North America Neurological Biomarkers Market Facts & Figures by Country
3.4.1 North America Neurological Biomarkers Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Neurological Biomarkers Sales by Country (2020-2031)
3.4.3 North America Neurological Biomarkers Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neurological Biomarkers Market Facts & Figures by Country
3.5.1 Europe Neurological Biomarkers Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Neurological Biomarkers Sales by Country (2020-2031)
3.5.3 Europe Neurological Biomarkers Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurological Biomarkers Market Facts & Figures by Region
3.6.1 Asia Pacific Neurological Biomarkers Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Neurological Biomarkers Sales by Region (2020-2031)
3.6.3 Asia Pacific Neurological Biomarkers Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neurological Biomarkers Market Facts & Figures by Country
3.7.1 Latin America Neurological Biomarkers Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Neurological Biomarkers Sales by Country (2020-2031)
3.7.3 Latin America Neurological Biomarkers Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurological Biomarkers Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurological Biomarkers Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Neurological Biomarkers Sales by Country (2020-2031)
3.8.3 Middle East and Africa Neurological Biomarkers Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neurological Biomarkers Sales by Type (2020-2031)
4.1.1 Global Neurological Biomarkers Sales by Type (2020-2025)
4.1.2 Global Neurological Biomarkers Sales by Type (2026-2031)
4.1.3 Global Neurological Biomarkers Sales Market Share by Type (2020-2031)
4.2 Global Neurological Biomarkers Revenue by Type (2020-2031)
4.2.1 Global Neurological Biomarkers Revenue by Type (2020-2025)
4.2.2 Global Neurological Biomarkers Revenue by Type (2026-2031)
4.2.3 Global Neurological Biomarkers Revenue Market Share by Type (2020-2031)
4.3 Global Neurological Biomarkers Price by Type (2020-2031)
5 Segment by Application
5.1 Global Neurological Biomarkers Sales by Application (2020-2031)
5.1.1 Global Neurological Biomarkers Sales by Application (2020-2025)
5.1.2 Global Neurological Biomarkers Sales by Application (2026-2031)
5.1.3 Global Neurological Biomarkers Sales Market Share by Application (2020-2031)
5.2 Global Neurological Biomarkers Revenue by Application (2020-2031)
5.2.1 Global Neurological Biomarkers Revenue by Application (2020-2025)
5.2.2 Global Neurological Biomarkers Revenue by Application (2026-2031)
5.2.3 Global Neurological Biomarkers Revenue Market Share by Application (2020-2031)
5.3 Global Neurological Biomarkers Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Thermo Fisher Scientific
6.1.1 Thermo Fisher Scientific Company Information
6.1.2 Thermo Fisher Scientific Description and Business Overview
6.1.3 Thermo Fisher Scientific Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Thermo Fisher Scientific Neurological Biomarkers Product Portfolio
6.1.5 Thermo Fisher Scientific Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck Neurological Biomarkers Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Quest Diagnostics
6.3.1 Quest Diagnostics Company Information
6.3.2 Quest Diagnostics Description and Business Overview
6.3.3 Quest Diagnostics Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Quest Diagnostics Neurological Biomarkers Product Portfolio
6.3.5 Quest Diagnostics Recent Developments/Updates
6.4 Abbott
6.4.1 Abbott Company Information
6.4.2 Abbott Description and Business Overview
6.4.3 Abbott Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Abbott Neurological Biomarkers Product Portfolio
6.4.5 Abbott Recent Developments/Updates
6.5 Roche
6.5.1 Roche Company Information
6.5.2 Roche Description and Business Overview
6.5.3 Roche Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Roche Neurological Biomarkers Product Portfolio
6.5.5 Roche Recent Developments/Updates
6.6 Illumina
6.6.1 Illumina Company Information
6.6.2 Illumina Description and Business Overview
6.6.3 Illumina Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Illumina Neurological Biomarkers Product Portfolio
6.6.5 Illumina Recent Developments/Updates
6.7 Bio-Rad Laboratories
6.7.1 Bio-Rad Laboratories Company Information
6.7.2 Bio-Rad Laboratories Description and Business Overview
6.7.3 Bio-Rad Laboratories Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bio-Rad Laboratories Neurological Biomarkers Product Portfolio
6.7.5 Bio-Rad Laboratories Recent Developments/Updates
6.8 QIAGEN
6.8.1 QIAGEN Company Information
6.8.2 QIAGEN Description and Business Overview
6.8.3 QIAGEN Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.8.4 QIAGEN Neurological Biomarkers Product Portfolio
6.8.5 QIAGEN Recent Developments/Updates
6.9 Myriad RBM
6.9.1 Myriad RBM Company Information
6.9.2 Myriad RBM Description and Business Overview
6.9.3 Myriad RBM Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Myriad RBM Neurological Biomarkers Product Portfolio
6.9.5 Myriad RBM Recent Developments/Updates
6.10 Cisbio Bioassays
6.10.1 Cisbio Bioassays Company Information
6.10.2 Cisbio Bioassays Description and Business Overview
6.10.3 Cisbio Bioassays Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Cisbio Bioassays Neurological Biomarkers Product Portfolio
6.10.5 Cisbio Bioassays Recent Developments/Updates
6.11 Athena Diagnostics
6.11.1 Athena Diagnostics Company Information
6.11.2 Athena Diagnostics Description and Business Overview
6.11.3 Athena Diagnostics Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Athena Diagnostics Neurological Biomarkers Product Portfolio
6.11.5 Athena Diagnostics Recent Developments/Updates
6.12 BGI
6.12.1 BGI Company Information
6.12.2 BGI Description and Business Overview
6.12.3 BGI Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.12.4 BGI Neurological Biomarkers Product Portfolio
6.12.5 BGI Recent Developments/Updates
6.13 Wuxi APP
6.13.1 Wuxi APP Company Information
6.13.2 Wuxi APP Description and Business Overview
6.13.3 Wuxi APP Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Wuxi APP Neurological Biomarkers Product Portfolio
6.13.5 Wuxi APP Recent Developments/Updates
6.14 Aepodia
6.14.1 Aepodia Company Information
6.14.2 Aepodia Description and Business Overview
6.14.3 Aepodia Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Aepodia Neurological Biomarkers Product Portfolio
6.14.5 Aepodia Recent Developments/Updates
6.15 Proteome Sciences
6.15.1 Proteome Sciences Company Information
6.15.2 Proteome Sciences Description and Business Overview
6.15.3 Proteome Sciences Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Proteome Sciences Neurological Biomarkers Product Portfolio
6.15.5 Proteome Sciences Recent Developments/Updates
6.16 Genewiz
6.16.1 Genewiz Company Information
6.16.2 Genewiz Description and Business Overview
6.16.3 Genewiz Neurological Biomarkers Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Genewiz Neurological Biomarkers Product Portfolio
6.16.5 Genewiz Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurological Biomarkers Industry Chain Analysis
7.2 Neurological Biomarkers Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurological Biomarkers Production Mode & Process Analysis
7.4 Neurological Biomarkers Sales and Marketing
7.4.1 Neurological Biomarkers Sales Channels
7.4.2 Neurological Biomarkers Distributors
7.5 Neurological Biomarkers Customer Analysis
8 Neurological Biomarkers Market Dynamics
8.1 Neurological Biomarkers Industry Trends
8.2 Neurological Biomarkers Market Drivers
8.3 Neurological Biomarkers Market Challenges
8.4 Neurological Biomarkers Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Neurological Biomarkers Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Neurological Biomarkers Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Neurological Biomarkers Market Competitive Situation by Manufacturers in 2024
Table 4. Global Neurological Biomarkers Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Neurological Biomarkers Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Neurological Biomarkers Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Neurological Biomarkers Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Neurological Biomarkers Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Neurological Biomarkers, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Neurological Biomarkers, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Neurological Biomarkers, Product Type & Application
Table 12. Global Key Manufacturers of Neurological Biomarkers, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Neurological Biomarkers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Biomarkers as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Neurological Biomarkers Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Neurological Biomarkers Sales by Region (2020-2025) & (K Units)
Table 18. Global Neurological Biomarkers Sales Market Share by Region (2020-2025)
Table 19. Global Neurological Biomarkers Sales by Region (2026-2031) & (K Units)
Table 20. Global Neurological Biomarkers Sales Market Share by Region (2026-2031)
Table 21. Global Neurological Biomarkers Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Neurological Biomarkers Revenue Market Share by Region (2020-2025)
Table 23. Global Neurological Biomarkers Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Neurological Biomarkers Revenue Market Share by Region (2026-2031)
Table 25. North America Neurological Biomarkers Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Neurological Biomarkers Sales by Country (2020-2025) & (K Units)
Table 27. North America Neurological Biomarkers Sales by Country (2026-2031) & (K Units)
Table 28. North America Neurological Biomarkers Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Neurological Biomarkers Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Neurological Biomarkers Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Neurological Biomarkers Sales by Country (2020-2025) & (K Units)
Table 32. Europe Neurological Biomarkers Sales by Country (2026-2031) & (K Units)
Table 33. Europe Neurological Biomarkers Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Neurological Biomarkers Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Neurological Biomarkers Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Neurological Biomarkers Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Neurological Biomarkers Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Neurological Biomarkers Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Neurological Biomarkers Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Neurological Biomarkers Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Neurological Biomarkers Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Neurological Biomarkers Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Neurological Biomarkers Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Neurological Biomarkers Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Neurological Biomarkers Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Neurological Biomarkers Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Neurological Biomarkers Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Neurological Biomarkers Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Neurological Biomarkers Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Neurological Biomarkers Sales (K Units) by Type (2020-2025)
Table 51. Global Neurological Biomarkers Sales (K Units) by Type (2026-2031)
Table 52. Global Neurological Biomarkers Sales Market Share by Type (2020-2025)
Table 53. Global Neurological Biomarkers Sales Market Share by Type (2026-2031)
Table 54. Global Neurological Biomarkers Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Neurological Biomarkers Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Neurological Biomarkers Revenue Market Share by Type (2020-2025)
Table 57. Global Neurological Biomarkers Revenue Market Share by Type (2026-2031)
Table 58. Global Neurological Biomarkers Price (USD/Unit) by Type (2020-2025)
Table 59. Global Neurological Biomarkers Price (USD/Unit) by Type (2026-2031)
Table 60. Global Neurological Biomarkers Sales (K Units) by Application (2020-2025)
Table 61. Global Neurological Biomarkers Sales (K Units) by Application (2026-2031)
Table 62. Global Neurological Biomarkers Sales Market Share by Application (2020-2025)
Table 63. Global Neurological Biomarkers Sales Market Share by Application (2026-2031)
Table 64. Global Neurological Biomarkers Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Neurological Biomarkers Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Neurological Biomarkers Revenue Market Share by Application (2020-2025)
Table 67. Global Neurological Biomarkers Revenue Market Share by Application (2026-2031)
Table 68. Global Neurological Biomarkers Price (USD/Unit) by Application (2020-2025)
Table 69. Global Neurological Biomarkers Price (USD/Unit) by Application (2026-2031)
Table 70. Thermo Fisher Scientific Company Information
Table 71. Thermo Fisher Scientific Description and Business Overview
Table 72. Thermo Fisher Scientific Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. Thermo Fisher Scientific Neurological Biomarkers Product
Table 74. Thermo Fisher Scientific Recent Developments/Updates
Table 75. Merck Company Information
Table 76. Merck Description and Business Overview
Table 77. Merck Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Merck Neurological Biomarkers Product
Table 79. Merck Recent Developments/Updates
Table 80. Quest Diagnostics Company Information
Table 81. Quest Diagnostics Description and Business Overview
Table 82. Quest Diagnostics Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Quest Diagnostics Neurological Biomarkers Product
Table 84. Quest Diagnostics Recent Developments/Updates
Table 85. Abbott Company Information
Table 86. Abbott Description and Business Overview
Table 87. Abbott Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Abbott Neurological Biomarkers Product
Table 89. Abbott Recent Developments/Updates
Table 90. Roche Company Information
Table 91. Roche Description and Business Overview
Table 92. Roche Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Roche Neurological Biomarkers Product
Table 94. Roche Recent Developments/Updates
Table 95. Illumina Company Information
Table 96. Illumina Description and Business Overview
Table 97. Illumina Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Illumina Neurological Biomarkers Product
Table 99. Illumina Recent Developments/Updates
Table 100. Bio-Rad Laboratories Company Information
Table 101. Bio-Rad Laboratories Description and Business Overview
Table 102. Bio-Rad Laboratories Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Bio-Rad Laboratories Neurological Biomarkers Product
Table 104. Bio-Rad Laboratories Recent Developments/Updates
Table 105. QIAGEN Company Information
Table 106. QIAGEN Description and Business Overview
Table 107. QIAGEN Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. QIAGEN Neurological Biomarkers Product
Table 109. QIAGEN Recent Developments/Updates
Table 110. Myriad RBM Company Information
Table 111. Myriad RBM Description and Business Overview
Table 112. Myriad RBM Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Myriad RBM Neurological Biomarkers Product
Table 114. Myriad RBM Recent Developments/Updates
Table 115. Cisbio Bioassays Company Information
Table 116. Cisbio Bioassays Description and Business Overview
Table 117. Cisbio Bioassays Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Cisbio Bioassays Neurological Biomarkers Product
Table 119. Cisbio Bioassays Recent Developments/Updates
Table 120. Athena Diagnostics Company Information
Table 121. Athena Diagnostics Description and Business Overview
Table 122. Athena Diagnostics Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Athena Diagnostics Neurological Biomarkers Product
Table 124. Athena Diagnostics Recent Developments/Updates
Table 125. BGI Company Information
Table 126. BGI Description and Business Overview
Table 127. BGI Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. BGI Neurological Biomarkers Product
Table 129. BGI Recent Developments/Updates
Table 130. Wuxi APP Company Information
Table 131. Wuxi APP Description and Business Overview
Table 132. Wuxi APP Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Wuxi APP Neurological Biomarkers Product
Table 134. Wuxi APP Recent Developments/Updates
Table 135. Aepodia Company Information
Table 136. Aepodia Description and Business Overview
Table 137. Aepodia Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Aepodia Neurological Biomarkers Product
Table 139. Aepodia Recent Developments/Updates
Table 140. Proteome Sciences Company Information
Table 141. Proteome Sciences Description and Business Overview
Table 142. Proteome Sciences Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 143. Proteome Sciences Neurological Biomarkers Product
Table 144. Proteome Sciences Recent Developments/Updates
Table 145. Genewiz Company Information
Table 146. Genewiz Description and Business Overview
Table 147. Genewiz Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 148. Genewiz Neurological Biomarkers Product
Table 149. Genewiz Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Neurological Biomarkers Distributors List
Table 153. Neurological Biomarkers Customers List
Table 154. Neurological Biomarkers Market Trends
Table 155. Neurological Biomarkers Market Drivers
Table 156. Neurological Biomarkers Market Challenges
Table 157. Neurological Biomarkers Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report
List of Figures
Figure 1. Product Picture of Neurological Biomarkers
Figure 2. Global Neurological Biomarkers Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neurological Biomarkers Market Share by Type: 2024 & 2031
Figure 4. Proteomics Product Picture
Figure 5. Genomics Product Picture
Figure 6. Imaging Product Picture
Figure 7. Bioinformatics Product Picture
Figure 8. Others Product Picture
Figure 9. Global Neurological Biomarkers Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global Neurological Biomarkers Market Share by Application: 2024 & 2031
Figure 11. Diagnostics
Figure 12. Drug Discovery
Figure 13. Personalized Medicine
Figure 14. Others
Figure 15. Global Neurological Biomarkers Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Neurological Biomarkers Market Size (2020-2031) & (US$ Million)
Figure 17. Global Neurological Biomarkers Sales (2020-2031) & (K Units)
Figure 18. Global Neurological Biomarkers Average Price (USD/Unit) & (2020-2031)
Figure 19. Neurological Biomarkers Report Years Considered
Figure 20. Neurological Biomarkers Sales Share by Manufacturers in 2024
Figure 21. Global Neurological Biomarkers Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest Neurological Biomarkers Players: Market Share by Revenue in Neurological Biomarkers in 2024
Figure 23. Neurological Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global Neurological Biomarkers Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America Neurological Biomarkers Sales Market Share by Country (2020-2031)
Figure 26. North America Neurological Biomarkers Revenue Market Share by Country (2020-2031)
Figure 27. U.S. Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe Neurological Biomarkers Sales Market Share by Country (2020-2031)
Figure 30. Europe Neurological Biomarkers Revenue Market Share by Country (2020-2031)
Figure 31. Germany Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific Neurological Biomarkers Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific Neurological Biomarkers Revenue Market Share by Region (2020-2031)
Figure 38. China Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Taiwan Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Indonesia Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Thailand Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Malaysia Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Philippines Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Latin America Neurological Biomarkers Sales Market Share by Country (2020-2031)
Figure 49. Latin America Neurological Biomarkers Revenue Market Share by Country (2020-2031)
Figure 50. Mexico Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Brazil Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Argentina Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Middle East and Africa Neurological Biomarkers Sales Market Share by Country (2020-2031)
Figure 54. Middle East and Africa Neurological Biomarkers Revenue Market Share by Country (2020-2031)
Figure 55. Turkey Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Saudi Arabia Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. U.A.E Neurological Biomarkers Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Global Sales Market Share of Neurological Biomarkers by Type (2020-2031)
Figure 59. Global Revenue Market Share of Neurological Biomarkers by Type (2020-2031)
Figure 60. Global Neurological Biomarkers Price (USD/Unit) by Type (2020-2031)
Figure 61. Global Sales Market Share of Neurological Biomarkers by Application (2020-2031)
Figure 62. Global Revenue Market Share of Neurological Biomarkers by Application (2020-2031)
Figure 63. Global Neurological Biomarkers Price (USD/Unit) by Application (2020-2031)
Figure 64. Neurological Biomarkers Value Chain
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
